Skip to content
Comparison

NAD+ vs SS-31 (Elamipretide)

NAD+ and SS-31 (Elamipretide) are commonly compared for NAD system replenishment versus mitochondrial membrane-targeted peptide. NAD+ is usually favored for broad metabolic coenzyme support, while SS-31 (Elamipretide) is often preferred for mitochondrial cardiolipin-focused rescue strategy. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For NAD system replenishment versus mitochondrial membrane-targeted peptide, the better choice depends on your primary endpoint. NAD+ is stronger when the priority is global metabolic-energy support. SS-31 (Elamipretide) is stronger when the priority is targeted mitochondrial dysfunction experimentation. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaNAD+SS-31 (Elamipretide)
Primary mechanismCoenzyme replenishment strategy for mitochondrial and metabolic pathwaysMitochondria-targeted peptide stabilizing cardiolipin and ETC function
Strongest clinical signalSignals for improved cellular energetics and metabolic resilienceSignals for mitochondrial disease and ischemia-related energy rescue
Typical dosing contextIV, IM, SC, or oral precursor protocols vary widelyInvestigational injectable protocols
AdministrationClinic infusions/injections or oral support stacksSubcutaneous or IV in trials
Evidence quality gradeModerate mechanistic evidence; heterogeneous clinical outcomesModerate translational evidence, indication-specific
Regulatory statusNot an FDA-approved disease-specific peptide therapyInvestigational, not broadly approved
Side-effect burdenGenerally tolerated; protocol quality and formulation matterGenerally tolerated in trials; long-term real-world data limited
Cost/access contextHigh for infusion-heavy protocolsAccess mostly through studies/expanded pathways
Best candidate profileEnergy/fatigue and metabolic-support strategiesMitochondrial dysfunction-focused experimental care plans
Main limitationOutcome heterogeneity and protocol standardization gapsLimited commercial availability and endpoint heterogeneity
Best use case in this comparisonglobal metabolic-energy supporttargeted mitochondrial dysfunction experimentation

When to Choose Each

Choose NAD+

Best for global metabolic-energy support.

Choose SS-31 (Elamipretide)

Best for targeted mitochondrial dysfunction experimentation.

Verdict

If the main goal is global metabolic-energy support, NAD+ is usually the better first-line choice. If the main goal is targeted mitochondrial dysfunction experimentation, SS-31 (Elamipretide) is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. NAD+ metabolism and its roles in cellular processes during ageing (2018) — PubMed
  2. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults (2021) — PubMed
  3. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging (2013) — PubMed
  4. Effect of oral nicotinamide mononucleotide (NMN) on plasma NMN concentration and safety in healthy Japanese men (2020) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Which has stronger evidence for NAD system replenishment versus mitochondrial membrane-targeted peptide — NAD+ or SS-31 (Elamipretide)?
NAD+ is graded as moderate mechanistic evidence; heterogeneous clinical outcomes evidence in this context, while SS-31 (Elamipretide) is graded as moderate translational evidence, indication-specific. In practice, strength depends on whether you prioritize global metabolic-energy support or targeted mitochondrial dysfunction experimentation. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can NAD+ and SS-31 (Elamipretide) be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next